Minerva Surgical, Inc. (UTRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
UTRS Stock Summary
- MINERVA SURGICAL INC's market capitalization of $5,214,335 is ahead of merely 1.31% of US-listed equities.
- UTRS's went public 1.12 years ago, making it older than just 1.33% of listed US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for UTRS comes in at -1,418.22% -- higher than that of merely 0.46% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to MINERVA SURGICAL INC, a group of peers worth examining would be STIM, MLSS, CDXC, HNST, and PLAG.
- To dig deeper into the stock's financial statements, go to UTRS's page on browse-edgar?action=getcompany&CIK=0001452965.
UTRS Valuation Summary
- UTRS's price/earnings ratio is -0.3; this is 101.2% lower than that of the median Technology stock.
- Over the past 14 months, UTRS's EV/EBIT ratio has gone up 52.5.
Below are key valuation metrics over time for UTRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| UTRS | 2022-12-02 | 0.1 | 0.2 | -0.3 | -1.6 |
| UTRS | 2022-12-01 | 0.1 | 0.2 | -0.3 | -1.6 |
| UTRS | 2022-11-30 | 0.1 | 0.2 | -0.3 | -1.6 |
| UTRS | 2022-11-29 | 0.1 | 0.3 | -0.3 | -1.6 |
| UTRS | 2022-11-28 | 0.1 | 0.2 | -0.3 | -1.6 |
| UTRS | 2022-11-25 | 0.1 | 0.2 | -0.3 | -1.6 |
UTRS Stock Price Chart Interactive Chart >
UTRS Price/Volume Stats
| Current price | $0.18 | 52-week high | $6.20 |
| Prev. close | $0.18 | 52-week low | $0.16 |
| Day low | $0.18 | Volume | 286,800 |
| Day high | $0.21 | Avg. volume | 81,302 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $2.31 | Market Cap | 5.19M |
Minerva Surgical, Inc. (UTRS) Company Bio
Minerva Surgical Inc., a commercial-stage medical technology company, focuses on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest UTRS News From Around the Web
Below are the latest news stories about MINERVA SURGICAL INC that investors may wish to consider to help them evaluate UTRS as an investment opportunity.
Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare ConferenceSANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY. A live audio webcast and replay of the presentation may be accessed through the “Recent Events” section of Minerva’s website at http:// |
Minerva Surgical Third Quarter 2022 Earnings: EPS Misses ExpectationsMinerva Surgical ( NASDAQ:UTRS ) Third Quarter 2022 Results Key Financial Results Revenue: US$12.6m (flat on 3Q 2021... |
Minerva Surgical Reports Third Quarter 2022 Financial ResultsSANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022. Third Quarter and Recent Business Highlights: Reported revenue of $12.6 million in the third quarter of 2022, compared with revenue of $12.5 million in the third quarter of 2021 and $13.0 million in |
Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference CallSANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call. It will now report its third quarter 2022 financial results on Monday, November 14, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. |
Minerva Surgical to Announce Third Quarter 2022 Financial ResultsSANTA CLARA, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access |
UTRS Price Returns
| 1-mo | -50.47% |
| 3-mo | -87.41% |
| 6-mo | -92.53% |
| 1-year | -96.73% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -96.50% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...